Tools
Ivabradine
Indications
FDA-Approved Indications
Ivabradine is FDA-approved in the United States for use in patients with symptoms due to stable heart failure and an ejection fraction of 35% or less to reduce their risk of hospital admission for worsening heart failure.[1][2][3] Patients on ivabradine therapy should have a resting heart rate of at least 70 bpm and be in normal sinus rhythm. They should also be receiving their maximum tolerated β-blocker dose or have a contraindication for β-blocker therapy. According to the American College of Cardiology (ACC) and American Heart Association (AHA) 2022 heart failure guidelines, ivabradine may be beneficial in reducing hospitalizations due to heart failure and mortality in patients with symptomatic, stable chronic heart failure with reduced ejection fraction (HFrEF), specifically those with a left ventricular ejection fraction (LVEF) less than 35%. This applies to patients receiving guideline-directed medical therapy (GDMT), including a β-blocker at the highest tolerated dose and a resting heart rate greater than 70 bpm while in sinus rhythm. Additionally, the network meta-analysis indicates that the combination of angiotensin-converting enzyme inhibitors, β-blockers, mineralocorticoid receptor antagonists, and ivabradine is effective in reducing hospitalizations for heart failure with a risk ratio (RR) of 0.27 (95% CI, 0.18-0.39).[4][5][6] The FDA has also approved ivabradine for children older than 6 months with symptomatic heart failure due to dilated cardiomyopathy.[7][8]
Off-Label Uses
In Europe, ivabradine is indicated for patients with heart failure and chronic stable angina.[9] According to the 2015 guidelines from the American College of Cardiology, American Heart Association, and Heart Rhythm Society, ivabradine is a reasonable option for managing patients with symptomatic inappropriate sinus tachycardia.[10][11][12] A pilot study demonstrates the feasibility of personalized perioperative ivabradine for heart rate management in surgical patients. The rationale lies in the association between heart rate and perioperative myocardial injury, suggesting ivabradine may reduce cardiac risk. Further trials are needed to assess its efficacy in higher-risk patients.[13] Additionally, ivabradine is being investigated for tachycardia-induced cardiomyopathy and focal atrial tachycardia in pediatric patients.[14] Ivabradine shows promise in reducing heart rate and improving quality of life in patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS); however, further studies are needed to confirm its broader therapeutic potential.[15][16] Ivabradine may be a safe and effective treatment for refractory postoperative junctional ectopic tachycardia in pediatric patients, with rapid action and minimal adverse effects. Further research is needed to establish optimal dosing and long-term safety.[17] In the BRAKE-AF trial, ivabradine reduced heart rate modestly in permanent atrial fibrillation but was less effective than digoxin. Ivabradine was better tolerated, with fewer serious adverse events.[18][19] https://www.sciencedirect.com/science/article/pii/S1547527123005490
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Ivabradine blocks the channel responsible for the cardiac pacemaker current, I(f), which regulates heart rate. This results in prolonged diastolic time and reduced heart rate.[20] Rapid resting heart rate can lead to detrimental effects on left ventricular function and has been associated with adverse outcomes in patients with cardiovascular disease. Therefore, reducing resting heart rate to reduce cardiovascular morbidity and mortality is a therapeutic target among drug manufacturers. Ivabradine reduces heart rate but does not affect myocardial contraction, relaxation, or ventricular repolarization.
Clinical Evidence
The SHIFT trial was a double-blind, placebo-controlled study of patients with symptomatic heart failure, ejection fraction (EF) less than or equal to 35%, in sinus rhythm with a heart rate of at least 70 bpm, who had been admitted for heart failure within the past year and were on stable heart failure treatment including β-blockers. Patients received ivabradine titrated to 7.5 mg twice a day or placebo. The goal was to determine if ivabradine would decrease hospitalizations and/or mortality due to heart failure. Ivabradine reduced the primary endpoint, which was a composite of hospital admissions due to heart failure and mortality. Bradycardia and visual adverse effects (phosphenes) occurred more in patients receiving ivabradine than those in the placebo group.[21][22][23][24]
The BEAUTIFUL trial was a randomized, placebo-controlled, multinational trial to test whether reducing heart rate with ivabradine affected cardiovascular morbidity and mortality in patients with coronary artery disease and EF less than 40%. Patients had a resting heart rate of at least 60 bpm. Patients received ivabradine 5 mg twice daily with a goal of 7.5 mg twice daily versus placebo. Most patients were also receiving β-blocker therapy. Ivabradine did not affect the primary composite endpoint of cardiovascular mortality, hospital admissions for myocardial infarctions, or worsening heart failure. In patients with heartbeats of 70 or greater, ivabradine reduced hospital admissions due to fatal or non-fatal myocardial infarction.[25]
SIGNIFY was a randomized trial that tested the addition of ivabradine to standard therapy in patients with stable coronary artery disease but no heart failure. Participants had to be at least 55 years old with a heart rate of at least 70 bpm.[26] The goal heart rate was 55 to 60 bpm. Patients received 10 mg of ivabradine twice a day or a placebo. The primary endpoint was a composite of death or non-fatal myocardial infarction. After 28 months, there was no significant difference between ivabradine and placebo. Bradycardia occurred more with ivabradine than with placebo. The primary endpoint was higher in patients in the ivabradine group who initially had angina that limited activity.
Pharmacokinetics
Absorption: Under fasting conditions, ivabradine reaches peak plasma concentrations approximately one hour after oral administration. Due to first-pass metabolism in the gastrointestinal tract and liver, its absolute oral bioavailability is about 40%. Food intake delays absorption by approximately one hour and increases plasma exposure by 20% to 40%. Therefore, ivabradine should be administered with food.
Distribution: Ivabradine is approximately 70% bound to plasma proteins. The volume of distribution at steady state is approximately 100 L.
Metabolism: Ivabradine undergoes extensive hepatic metabolism via CYP3A4-mediated oxidation in the liver and intestines. The major metabolite, N-desmethyl ivabradine, possesses similar pharmacological activity as the parent compound and is present at approximately 40% of ivabradine’s plasma concentration. This metabolite is also further metabolized by CYP3A4.[27]
Elimination: Ivabradine’s plasma concentration declines with a distribution half-life of 2 hours and an effective elimination half-life of about 6 hours. The total clearance is 24 L/h, with renal clearance accounting for approximately 4.2 L/h. Approximately 4% of the administered dose is excreted unchanged in the urine, while metabolites are primarily excreted via the feces and urine.
Administration
Available Dosage Forms and Strengths
Ivabradine is available in oral tablet formulations of 5 mg, 7.5 mg, and as an oral solution of 5 mg/5 mL (1 mg/mL). The tablets are scored and can be divided into 2.5 mg doses.
Adult Dosage
The following describes the appropriate dosing of ivabradine for adults and children weighing more than 40 kg:
- The initial dose should be 5 mg twice daily.
- The dose can be adjusted after 2 weeks based on the heart rate.
- The maximum dose is 7.5 mg twice daily.
- Patients with conduction defects or bradycardia can be initiated on 2.5 mg twice daily.
- The reduction in heart rate depends on the baseline heart rate and the ivabradine dose.
Dose Adjustment
- If the heart rate is more than 60 bpm, the dose should be increased by 2.5 mg twice daily, up to 7.5 mg daily.
- If the heart rate is 50 to 60 bpm, the current dose should be continued.
- If the heart rate is less than 50 bpm or the patient is experiencing symptoms of bradycardia, the dose should be reduced by 2.5 mg twice daily. Ivabradine therapy may cease entirely if the dose reaches 2.5 mg twice daily.
Specific Patient Populations
Hepatic impairment: No dose adjustment is required for mild or moderate hepatic impairment. However, ivabradine is contraindicated for patients with severe hepatic impairment (Child-Pugh C) due to a lack of studies in this population and anticipated increased systemic exposure.
Renal impairment: No dosage adjustment for ivabradine is necessary for creatinine clearance of 15 to 60 mL/min. No clinical data is available for patients with less than 15 mL/min creatinine clearance. Ivabradine reduced dialysis-related hypotension and heart rate in hemodialysis patients with chronic heart failure, showing potential to improve quality of life. However, further research is required.[28]
Pregnancy considerations: An observational study of ivabradine exposure during pregnancy found no significant teratogenic effects, with one case of congenital disabilities (tracheal atresia). However, due to adverse outcomes in animal studies and the lack of human data, ivabradine is contraindicated in pregnancy, and alternative treatments with established safety profiles should be prioritized.[29] Clinicians should recommend that females of reproductive potential use reliable contraception during ivabradine treatment.
Breastfeeding considerations: According to the product label, there is no data on ivabradine in human milk or its effects on breastfed infants or milk production. Animal studies have shown ivabradine is present in rat milk, so breastfeeding is not recommended due to potential risks to infants.[30]
Pediatric patients: The safety and efficacy of ivabradine have been established in pediatric patients aged 6 months to 18 years. For patients weighing less than 40 kg, the initial dose is 0.05 mg/kg twice daily with food. Dose adjustments of 0.05 mg/kg can be made every 2 weeks based on heart rate. The maximum dose is 0.2 mg/kg for patients aged 6 months to less than 1 year and 0.3 mg/kg for patients aged 1 year and older, with a maximum daily dose of 7.5 mg, administered twice daily.
Older patients: Ivabradine demonstrates no significant differences in patients 65 or older compared to younger patients. The effects of this medication are currently under study for patients aged 75 and older.
Adverse Effects
The most common adverse effects associated with ivabradine administration include bradycardia, atrial fibrillation, high blood pressure, and phosphenes.
Ivabradine can cause bradycardia, sinus arrest, and heart block. Sinus node dysfunction, first- or second-degree atrioventricular block, bundle branch block, ventricular dyssynchrony, and or concomitant use of other heart-rate-reducing drugs increase the risk of bradycardia. In the SHIFT trial, symptomatic bradycardia occurred in 5% of patients taking ivabradine compared to 1% in the placebo group. Asymptomatic bradycardia occurred in 6% of patients on ivabradine compared to 1% in the placebo group. Bradycardia led to permanent withdrawal from the study in 1% of patients on ivabradine and less than 1% of those in the placebo group. QT prolongation, torsade de pointes, and other arrhythmias may occur due to ivabradine-induced bradycardia.[31]
Ivabradine increases the risk of atrial fibrillation. Discontinue ivabradine if atrial fibrillation occurs.
Visual adverse effects (phosphenes/luminous phenomena) have been observed.[32] Possible explanations include ivabradine's inhibition of the retina's I(h) current. During the SHIFT trial, known phosphenes occurred in 3% of patients taking the ivabradine compared to less than 1% in the placebo group. This difference in the occurrence of phosphenes was statistically significant.[32][33]
Postmarketing adverse effects of ivabradine include syncope, hypotension, angioedema, erythema, rash, pruritus, vertigo, and diplopia.[3]
Drug-Drug Interactions
- Negative chronotropic drugs: A significant proportion of patients who are prescribed ivabradine also receive treatment with a β-blocker. When ivabradine is combined with other medications that decrease heart rate, including digoxin, amiodarone, or additional β-blockers, the probability of bradycardia increases.[34] Therefore, it is essential to monitor heart rate closely in patients who are administered ivabradine alongside these negative chronotropic agents.
- CYP3A4 inducers: CYP3A4 inducers, such as St. John's wort, rifampicin, barbiturates, and phenytoin, should be avoided during ivabradine therapy.[35]
- CYP3A4 inhibitors: CYP3A4 metabolizes ivabradine. Administering CYP3A4 inhibitors increases ivabradine plasma concentrations, while CYP3A4 inducers reduce them. Increased ivabradine levels may potentiate bradycardia and conduction abnormalities. The co-administration of potent CYP3A4 inhibitors with ivabradine is contraindicated. Strong inhibitors include azole antifungals such as itraconazole, macrolide antibiotics such as telithromycin and clarithromycin, HIV protease inhibitors, and nefazodone.[36] Verapamil and diltiazem are also CYP3A4 inhibitors; they increase ivabradine levels and, hence, the risk of bradycardia.[37]
Contraindications
Ivabradine is contraindicated for patients with the following conditions:
- Decompensated heart failure
- Blood pressure less than 90/50 mm Hg
- Conduction abnormalities (eg, sick sinus syndrome, sinoatrial block, or third-degree AV block) unless a pacemaker determines the heart rate
- Severe liver impairment
- Patients taking cytochrome P450 3A4 (CYP3A4) inhibitors
- Resting heart rate less than 60 bpm before therapy is initiated [38]
Warning and Precautions
- Atrial fibrillation
- 2nd-degree AV block
- bradycardia [31]
Monitoring
The following are recommendations for monitoring patients receiving ivabradine:
Toxicity
Signs and Symptoms of Overdose
Ivabradine overdose often presents with severe sinus bradycardia and prolonged periods of asystole, which can be refractory to atropine. Symptoms include a significant reduction in heart rate, with some cases presenting a nadir as low as 15 bpm. The toxicity may be influenced by the severity of the overdose and the individual's serum levels of ivabradine. Additionally, overdose can lead to prolonged sinus node recovery time and QT interval, potentially increasing the risk of arrhythmias, including atrial fibrillation and torsades de pointes. Fatal intoxication has also been reported.[39]
Management of Overdose
Management of ivabradine overdose focuses on reversing the bradycardia and stabilizing the heart rate. There is no antidote for ivabradine. IV fluids and supportive treatment should be provided. Dopamine and isoproterenol can increase heart rate temporarily, but in some cases, a temporary pacemaker may be necessary to maintain adequate cardiac output.[40]
Enhancing Healthcare Team Outcomes
Ivabradine is FDA-approved in the United States for use in patients with symptoms due to stable heart failure and an ejection fraction of 35% or less to reduce their risk of hospital admission for worsening heart failure. An interprofessional team usually manages heart failure, including a cardiologist, intensivist, internist, nephrologist, pulmonologist, family medicine, nursing staff, and pharmacist. Healthcare professionals who prescribe ivabradine should monitor the patient's heart rate regularly. This medication can cause bradycardia, and drug interactions should be kept in mind.[41][42] Cardiologists prescribe ivabradine for heart failure, closely monitoring patient response, particularly heart rate. Pharmacists ensure appropriate dosing, identify potential drug interactions, and provide patient education regarding the proper use and adverse effects of ivabradine. Nurses monitor patients for bradycardia and overall clinical status. Primary care physicians manage comorbidities and collaborate with specialists to ensure proper follow-up. Emergency care physicians are responsible for treating ivabradine overdose or toxicity, focusing on managing bradycardia and potential arrhythmias. An interprofessional team approach and communication among clinicians are crucial to decreasing potential adverse effects and improving patient outcomes related to ivabradine pharmacotherapy.
References
Krajcirovicova K, Aziriova S, Baka T, Repova K, Adamcova M, Paulis L, Simko F. Ivabradine does not impair anxiety-like behavior and memory in both healthy and L-NAME-induced hypertensive rats. Physiological research. 2018 Dec 31:67(Suppl 4):S655-S664 [PubMed PMID: 30607972]
Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the Treatment of Cardiovascular Diseases. Circulation journal : official journal of the Japanese Circulation Society. 2019 Jan 25:83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29 [PubMed PMID: 30606942]
Sathyamurthy I, Newale S. Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian heart journal. 2018 Dec:70 Suppl 3(Suppl 3):S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20 [PubMed PMID: 30595304]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1 [PubMed PMID: 35363499]
Level 1 (high-level) evidenceWaranugraha Y, Rizal A, Tjahjono CT, Vilado IY, David NI, Abudan F, Setyaningrum DA. A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients. Heart, lung & circulation. 2024 Jul:33(7):962-974. doi: 10.1016/j.hlc.2023.09.005. Epub 2024 May 10 [PubMed PMID: 38729854]
Level 1 (high-level) evidenceTang H, Germinal K, Milfort A, Chen WH, Chang SH, Huang W, Li Y, Lu Y, Ahmed MM, Kimmel SE, Bian J, Guo J. The most effective combination of pharmacological therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomized controlled trials. BMC cardiovascular disorders. 2024 Nov 23:24(1):666. doi: 10.1186/s12872-024-04339-3. Epub 2024 Nov 23 [PubMed PMID: 39578732]
Level 1 (high-level) evidenceLoss KL, Shaddy RE, Kantor PF. Recent and Upcoming Drug Therapies for Pediatric Heart Failure. Frontiers in pediatrics. 2021:9():681224. doi: 10.3389/fped.2021.681224. Epub 2021 Nov 11 [PubMed PMID: 34858897]
Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology. 2017 Sep 5:70(10):1262-1272. doi: 10.1016/j.jacc.2017.07.725. Epub [PubMed PMID: 28859790]
Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. Journal of the American College of Cardiology. 2017 Oct 3:70(14):1777-1784. doi: 10.1016/j.jacc.2017.08.038. Epub [PubMed PMID: 28958335]
Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NA 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM, Evidence Review Committee Chair‡. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016 Apr 5:133(14):e506-74. doi: 10.1161/CIR.0000000000000311. Epub 2015 Sep 23 [PubMed PMID: 26399663]
Level 1 (high-level) evidenceHajiqasemi M, Ebrahimzade M, Ghelichkhan ZA, Huang X, Morkos D, Jennings D, Talasaz AH. Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review. Journal of cardiovascular pharmacology. 2024 Sep 1:84(3):276-288. doi: 10.1097/FJC.0000000000001609. Epub 2024 Sep 1 [PubMed PMID: 39027978]
Level 1 (high-level) evidenceGraziano F, Pizzolato M, Bondarev S, Corrado D, Zorzi A. Paradoxical improvement in exercise tolerance and peak VO2 consumption after treatment with ivabradine and beta-blockers in a patient with mild dilated cardiomyopathy and inappropriate sinus tachycardia-a case report. European heart journal. Case reports. 2025 Jan:9(1):ytae671. doi: 10.1093/ehjcr/ytae671. Epub 2024 Dec 18 [PubMed PMID: 39748935]
Level 3 (low-level) evidenceWhite MJ, Zaccaria I, Ennahdi-Elidrissi F, Putzu A, Dimassi S, Luise S, Diaper J, Mulin S, Baudat AD, Gil-Wey B, Elia N, Walder B, Bollen Pinto B. Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial. British journal of anaesthesia. 2024 Oct:133(4):738-747. doi: 10.1016/j.bja.2024.05.020. Epub 2024 Jul 2 [PubMed PMID: 38960832]
Level 1 (high-level) evidenceXu X, Guo Y, Gao W, Huang M, Liu T, Li F. Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study. European journal of pediatrics. 2023 May:182(5):2265-2271. doi: 10.1007/s00431-023-04891-8. Epub 2023 Mar 4 [PubMed PMID: 36869903]
Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. Journal of the American College of Cardiology. 2021 Feb 23:77(7):861-871. doi: 10.1016/j.jacc.2020.12.029. Epub [PubMed PMID: 33602468]
Level 1 (high-level) evidenceVasavada AM, Verma D, Sheggari V, Ghetiya S, Chirumamilla PC, Kotak RA, Mahapatra SS, Patel T, Jain M. Choices and Challenges With Drug Therapy in Postural Orthostatic Tachycardia Syndrome: A Systematic Review. Cureus. 2023 May:15(5):e38887. doi: 10.7759/cureus.38887. Epub 2023 May 11 [PubMed PMID: 37313107]
Level 1 (high-level) evidenceLópez Fernández E, Montañes Delmas E, Granados Ruiz MÁ, Oviedo Melgares L, Ramos Casado V. Use of ivabradine in pediatric post-operative junctional ectopic tachycardia. Anales de pediatria. 2021 Aug:95(2):118-120. doi: 10.1016/j.anpede.2020.09.008. Epub 2021 Jul 20 [PubMed PMID: 34294598]
Fontenla A, Tamargo J, Salgado R, López-Gil M, Mejía E, Matía R, Toquero J, Montilla I, Rajjoub EA, García-Fernandez FJ, Miracle A, Rey JR, Bueno H, BRAKE-AF Study Investigators. Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial. Heart rhythm. 2023 Jun:20(6):822-830. doi: 10.1016/j.hrthm.2023.02.012. Epub [PubMed PMID: 37245897]
Fontenla A, López-Gil M, Tamargo-Menéndez J, Matía-Francés R, Salgado-Aranda R, Rey-Blas JR, Miracle-Blanco Á, Mejía-Martínez E, Pastor-Fuentes A, Toquero-Ramos J, Arias MÁ, Montilla I, Gómez de la Cámara A, Arribas F, BRAKE-AF investigators. Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project. Revista espanola de cardiologia (English ed.). 2020 May:73(5):368-375. doi: 10.1016/j.rec.2019.09.004. Epub 2019 Oct 17 [PubMed PMID: 31631048]
Pavasini R, Camici PG, Crea F, Danchin N, Fox K, Manolis AJ, Marzilli M, Rosano GMC, Lopez-Sendon JL, Pinto F, Balla C, Ferrari R. Anti-anginal drugs: Systematic review and clinical implications. International journal of cardiology. 2019 May 15:283():55-63. doi: 10.1016/j.ijcard.2018.12.008. Epub 2018 Dec 4 [PubMed PMID: 30538056]
Level 1 (high-level) evidenceOsmanska J, Jhund PS. Contemporary Management of Heart Failure in the Elderly. Drugs & aging. 2019 Feb:36(2):137-146. doi: 10.1007/s40266-018-0625-4. Epub [PubMed PMID: 30535931]
Ennezat PV, Le Jemtel T, Cosgrove S, Hallas J, Hansen MR. Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. Acta cardiologica. 2020 Feb:75(1):10-19. doi: 10.1080/00015385.2018.1534769. Epub 2018 Dec 4 [PubMed PMID: 30513258]
Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Therapeutic advances in chronic disease. 2018 Nov:9(11):199-207. doi: 10.1177/2040622318784556. Epub 2018 Jul 4 [PubMed PMID: 30364460]
Level 3 (low-level) evidenceHartmann C, Bosch NL, de Aragão Miguita L, Tierie E, Zytinski L, Baena CP. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. International journal of clinical pharmacy. 2018 Dec:40(6):1443-1453. doi: 10.1007/s11096-018-0715-8. Epub 2018 Sep 1 [PubMed PMID: 30173307]
Level 1 (high-level) evidenceFox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2008 Sep 6:372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29 [PubMed PMID: 18757088]
Level 1 (high-level) evidenceFox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. American heart journal. 2013 Oct:166(4):654-661.e6. doi: 10.1016/j.ahj.2013.06.024. Epub 2013 Sep 17 [PubMed PMID: 24093844]
Level 1 (high-level) evidenceDesingu R, Kaore S, Kandelwal G, Balakrishnan S. Evaluation of ivabradine plus beta-blocker versus beta-blocker alone in addition to standard care in reducing hospitalization and major adverse cardiovascular event in patients with chronic heart failure: a prospective observational study in tertiary care hospital in central India. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology. 2024 May 31:76(1):67. doi: 10.1186/s43044-024-00500-7. Epub 2024 May 31 [PubMed PMID: 38819505]
Level 2 (mid-level) evidenceKawasaki S, Sakai Y, Harasawa S, Inatsu A, Kubota Y, Hirama A, Kashiwagi T, Iwabu M. The efficacy and safety of ivabradine hydrochloride in hemodialysis patients with chronic heart failure. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2024 Jun:28(3):354-363. doi: 10.1111/1744-9987.14107. Epub 2024 Jan 10 [PubMed PMID: 38199237]
Hoeltzenbein M, Lehmann ML, Beck E, Dathe K, Schaefer C. Ivabradine use in pregnant women-treatment indications and pregnancy outcome: an evaluation of the German Embryotox database. European journal of clinical pharmacology. 2021 Jul:77(7):1029-1037. doi: 10.1007/s00228-020-03066-w. Epub 2021 Jan 26 [PubMed PMID: 33501507]
Kearney L, Wright P, Fhadil S, Thomas M. Postpartum Cardiomyopathy and Considerations for Breastfeeding. Cardiac failure review. 2018 Aug:4(2):112-118. doi: 10.15420/cfr.2018.21.2. Epub [PubMed PMID: 30206487]
Romero-León JM, Gálvez-Contreras MC, Díez-García LF. Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy. Revista espanola de cardiologia (English ed.). 2016 May:69(5):529-30. doi: 10.1016/j.rec.2016.02.005. Epub 2016 Mar 21 [PubMed PMID: 27012681]
Towheed A, Nesheiwat Z, Mangi MA, Karabin B, Grubb BP. Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study. Cardiology in the young. 2020 Jul:30(7):975-979. doi: 10.1017/S1047951120001341. Epub 2020 Jun 5 [PubMed PMID: 32498748]
Level 2 (mid-level) evidenceSwedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (London, England). 2010 Sep 11:376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Epub [PubMed PMID: 20801500]
Level 1 (high-level) evidenceMenezes MS, Doria GAA, Valença-Feitosa F, Pereira SN, Silvestre CC, de Oliveira Filho AD, Lobo IMF, Quintans-Júnior LJ. Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials. Exploratory research in clinical and social pharmacy. 2024 Jun:14():100435. doi: 10.1016/j.rcsop.2024.100435. Epub 2024 Apr 8 [PubMed PMID: 38646469]
Level 1 (high-level) evidenceVlase L, Popa A, Neag M, Muntean D, Leucuta SE. Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. Clinical drug investigation. 2012 Aug 1:32(8):533-8 [PubMed PMID: 22765768]
Kaski JC, Gloekler S, Ferrari R, Fox K, Lévy BI, Komajda M, Vardas P, Camici PG. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open heart. 2018:5(1):e000725. doi: 10.1136/openhrt-2017-000725. Epub 2018 Mar 9 [PubMed PMID: 29632676]
Cada DJ, Bindler R, Baker DE. Ivadradine. Hospital pharmacy. 2015 Oct:50(9):806-17. doi: 10.1310/hpj5009-806. Epub 2015 Oct 14 [PubMed PMID: 26912922]
Mohan JC, Sathyamurthy I, Panja M, Agarwala R, Ponde CK, Kumar AS, Mahala BK, Kolapkar V, Kumar RVL, Patel K. Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India. Current cardiology reviews. 2023:19(5):97-106. doi: 10.2174/1573403X19666230320105623. Epub [PubMed PMID: 36941812]
Level 3 (low-level) evidenceKnapp-Gisclon A, Zerah M, Mayer-Duverneuil C, Rambaud C, de la Grandamison GL, Alvarez JC. Fatal intoxication with ivabradine: First case report. Forensic science international. 2020 Jun:311():110288. doi: 10.1016/j.forsciint.2020.110288. Epub 2020 Apr 8 [PubMed PMID: 32311649]
Level 3 (low-level) evidenceOsei K, Taskesen T, Goerbig-Campbell J, Hounshell T. Ivabradine toxicity: A case report and review. HeartRhythm case reports. 2020 Apr:6(4):183-186. doi: 10.1016/j.hrcr.2019.12.007. Epub 2020 Jan 7 [PubMed PMID: 32322492]
Level 3 (low-level) evidenceBirkhoelzer S, Stevens D, Zachariah D, Taylor J, Rowell N, Kalra PR. Ivabradine tolerability in heart failure. Journal of geriatric cardiology : JGC. 2018 Nov:15(11):708-709. doi: 10.11909/j.issn.1671-5411.2018.11.007. Epub [PubMed PMID: 30534146]
Dodd K, Lampert BC. The Use and Indication of Ivabradine in Heart Failure. Heart failure clinics. 2018 Oct:14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18 [PubMed PMID: 30266358]